Korean
PRODUCTS
L-Arginine HCI
L-Arginine hydrochloride 10% Inj.
Protect the body against toxic effects by converting Ammonia into Urea Treatment of elemental circuit such as hyperammonemia by excretion of ammonia produced during the metabolic process by acting on the elemental circuit.
Nitric oxide production relaxes arteries to smooth blood flow.
It plays an essential role in the production of nitric oxide (NO). Nitric oxide produced by arginine is a relaxation factor derived from endothelial cells.
It acts as a powerful vasoconstrictor to smooth blood flow and improve circulatory diseases such as coronary heart disease and hypertension.
Induces secretion of growth hormone, insulin, and others.
It acts on growth hormone, insulin, prolactin, glucagon, etc. by stimulating secretion of pituitary hormone by affecting the hypothalamus.
It also has anti-arteriosclerotic effect, antioxidant effect, immune control function, wound healing, kidney disease prevention,
and cystitis treatment effect, male erectile dysfunction treatment effect, Promoting sperm production, treating infertility with zinc
and carnitine and coenzyme Q10, promoting growth hormone release and muscle preservation,
reducing body fat and has a variety of effects and roles.
| Product name | L-Arginine hydrochloride 10% Inj. L-Arginine hydrochloride 10% Inj |
|
| Ingredients · Content | L-Arginine hydrochloride 10% • 100mg/1ml | |
| Classification · Code | Specialty medicines / not classified Metabolic Medicine (399) | |
| Appearance | A clear, colorless transparent solution injected into a colorless transparent glass or plastic container | |
| Efficacy · effect | If acute exacerbation of hyperammonemia due to the following diseases is not possible to control by oral administration, decrease of blood ammonia concentration 1) Abnormal urea line - Caebamtl phosphate systhetase (CPS) deficiency - Ornitine transcarbamylase (OTC) deficiency - Arginosuccinate synthetase (ASS) deficiency - Arginosuccinate lyase (ASL) deficiency 2) Lysinuric protein intolerance <Notes on efficacy> In principle, the diagnosis is confirmed and administered to patients who have been treated through adjuvant therapy such as arginine. However, in case of urgent administration to a patient whose congenital uremic cycle abnormality is predicted, the patient should be administered regarding blood ammonia concentration and symptom confirmation. |
|
| Usage · Capacity | 0.2-1 g of arginine hydrochloride per kg of the patient's body weight and is gradually injected intravenously over 1 hour. | |
| Packing Unit | 100ml / bottle | |
